Analyst Price Targets — KYTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 16, 2025 11:47 am | — | Wells Fargo | $33.00 | $10.81 | TheFly | Kyverna Therapeutics price target raised to $33 from $31 at Wells Fargo |
| December 15, 2025 8:09 pm | — | UBS | $32.00 | $10.81 | TheFly | Leerink raises Kyverna price target, says KYSA-8 study results transformative |
| December 15, 2025 7:26 pm | Michael Ulz | Morgan Stanley | $33.00 | $10.81 | TheFly | Kyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley |
| December 4, 2025 1:36 pm | Michael Ulz | Morgan Stanley | $25.00 | $7.79 | TheFly | Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley |
| October 27, 2025 10:19 am | — | H.C. Wainwright | $20.00 | $7.44 | TheFly | Kyverna Therapeutics price target raised to $20 from $10 at H.C. Wainwright |
| August 29, 2025 10:08 am | — | H.C. Wainwright | $10.00 | $3.71 | TheFly | Kyverna Therapeutics price target raised to $10 from $5 at H.C. Wainwright |
Latest News for KYTX
Kyverna Therapeutics, Inc. (NASDAQ: KYTX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month target price among analysts
EMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced it will host a conference call on Wednesday, April 22, 2026 at 7:00 a.m.
Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026
Kyverna Therapeutics, Inc. (NASDAQ: KYTX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1
Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KYTX.
U.S. House Trading
No House trades found for KYTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.